ReviewPediatric dermatology
Prevention of Atopic Dermatitis in High-Risk Infants: A Review of the Role of Lipid-Based Barrier Repair Therapy.
Review in Pediatric dermatology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
objectiveGrowing evidence highlights the role of physiological lipids, namely ceramides, cholesterol, and free fatty acids, in maintaining skin barrier function and preventing atopic dermatitis (AD). Current evidence on the efficacy, safety, and clinical relevance of stratum corneum (SC) lipid-based therapies to prevent AD and increase skin barrier integrity in high-risk infants was reviewed and synthesized.
methodsSearches with key words lipid-based therapy, atopic dermatitis, infant, and prevention were conducted to identify papers using PubMed, Embase, Cochrane Library, and Scopus databases from January 2000 to June 2024.
resultsSC lipid-based therapies were reported to replenish deficient SC lipids, thereby improving skin barrier function, a critical aspect of AD management. These therapies reduced SCORAD scores, enhanced hydration, and improved epidermal cohesion, with some studies reporting comparable efficacy to topical corticosteroids when used as adjunct treatments. However, evidence supporting their effectiveness in preventing AD onset in infants remains limited, with only trends toward reduced AD incidence and food sensitization reported, without statistical significance. Importantly, SC lipid therapies are well tolerated, with no significant adverse effects noted, supporting their safety in infants and children.
conclusionThis review ascertained knowledge gaps that can direct research and resolve controversies regarding emollients. Mechanistic studies in high-risk and non-atopic infants, starting at birth, are warranted using within-subject comparisons and frequent evaluations, including SC sampling for proteomics and lipidomics outcomes for mechanistic insight. Studies should begin with relatively simple formulations, for example, containing only ceramides, cholesterol, and fatty acids matched to varying infant SC lipid profiles at birth and over time.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.